| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Commercial Officer
1 company
McKechnie Duncan serves as an EVP, Chief Commercial Officer at VRTX. Across recent SEC filings that breaks down to 0 buys and 5 sells. Those positions are worth an estimated $5.7M at current prices.
The biggest single holding is VRTX (~$5.7M) as EVP, Chief Commercial Officer. The recent filings there lean toward selling, a net 11,521 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | VRTX Vertex Pharmaceuticals Incorporated | EVP, Chief Commercial Officer | Sell | 1,541 | $519.00 | $799,779.00 | -12.3% | |
| Mar 11, 2026 | VRTX Vertex Pharmaceuticals Incorporated | EVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1,312,339.86 | -17.4% | |
| Mar 4, 2026 | VRTX Vertex Pharmaceuticals Incorporated | EVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1,158,306.10 | -13.9% | |
| Feb 25, 2026 | VRTX Vertex Pharmaceuticals Incorporated | EVP, Chief Commercial Officer | Sell | 4,910 | $487.65 | $2,394,365.00 | -21.9% |